Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 6
1991 8
1992 5
1993 24
1994 34
1995 48
1996 75
1997 85
1998 109
1999 143
2000 167
2001 176
2002 205
2003 195
2004 197
2005 208
2006 213
2007 254
2008 237
2009 218
2010 237
2011 202
2012 221
2013 238
2014 246
2015 241
2016 264
2017 229
2018 214
2019 214
2020 243
2021 220
2022 177
2023 168
2024 56

Text availability

Article attribute

Article type

Publication date

Search Results

5,260 results

Results by year

Filters applied: . Clear all
Page 1
The effects of inhaled corticosteroids on healthy airways.
Marchi E, Hinks TSC, Richardson M, Khalfaoui L, Symon FA, Rajasekar P, Clifford R, Hargadon B, Austin CD, MacIsaac JL, Kobor MS, Siddiqui S, Mar JS, Arron JR, Choy DF, Bradding P. Marchi E, et al. Allergy. 2024 Apr 30. doi: 10.1111/all.16146. Online ahead of print. Allergy. 2024. PMID: 38686450
METHODS: Randomized open-label bronchoscopy study of high-dose ICS therapy in 30 healthy adult volunteers randomized 2:1 to (i) fluticasone propionate 500 mcg bd daily or (ii) no treatment, for 4 weeks. ...
METHODS: Randomized open-label bronchoscopy study of high-dose ICS therapy in 30 healthy adult volunteers randomized 2:1 to (i) fluticaso …
Intranasal antihistamines and corticosteroids in allergic rhinitis: A systematic review and meta-analysis.
Sousa-Pinto B, Vieira RJ, Brozek J, Cardoso-Fernandes A, Lourenço-Silva N, Ferreira-da-Silva R, Ferreira A, Gil-Mata S, Bedbrook A, Klimek L, Fonseca JA, Zuberbier T, Schünemann HJ, Bousquet J. Sousa-Pinto B, et al. J Allergy Clin Immunol. 2024 Apr 27:S0091-6749(24)00419-6. doi: 10.1016/j.jaci.2024.04.016. Online ahead of print. J Allergy Clin Immunol. 2024. PMID: 38685482
Both in perennial and seasonal AR, most assessed treatments were more effective than placebo. In seasonal AR, azelastine-fluticasone, fluticasone furoate and fluticasone propionate were the medications with the highest probability of resulting in moderate or …
Both in perennial and seasonal AR, most assessed treatments were more effective than placebo. In seasonal AR, azelastine-fluticasone, …
Preclinical evaluation of novel synthesised nanoparticles based on tyrosine poly(ester amide) for improved targeted pulmonary delivery.
Dahmash EZ, Achkar NR, Ali DK, Jarrar Q, Iyire A, Assaf SM, Alyami H. Dahmash EZ, et al. Sci Rep. 2024 Apr 29;14(1):9845. doi: 10.1038/s41598-024-59588-1. Sci Rep. 2024. PMID: 38684750 Free PMC article.
Therefore, this project aimed to employ nanotechnology to develop a FDC of DPIs for market-leading medicines-fluticasone propionate (FP) and salmeterol xinafoate (SAL)-for asthma management. ...
Therefore, this project aimed to employ nanotechnology to develop a FDC of DPIs for market-leading medicines-fluticasone propionate ( …
Pharmacokinetic Models for Inhaled Fluticasone Propionate and Salmeterol Xinafoate to Quantify Batch-to-Batch Variability.
Li S, Feng K, Lee J, Gong Y, Wu F, Newman B, Yoon M, Fang L, Zhao L, Gobburu JVS. Li S, et al. AAPS J. 2024 Apr 26;26(3):56. doi: 10.1208/s12248-024-00913-x. AAPS J. 2024. PMID: 38671158 Clinical Trial.
Advair Diskus is an essential treatment for asthma and chronic obstructive pulmonary disease. It is a dry powder inhaler with a combination of fluticasone propionate (FP) and salmeterol xinafoate (SX). However, the pharmacokinetics (PK) batch-to-batch variability of the re …
Advair Diskus is an essential treatment for asthma and chronic obstructive pulmonary disease. It is a dry powder inhaler with a combination …
Intraclass comparison of inhaled corticosteroids for the risk of pneumonia in chronic obstructive pulmonary airway disorder: a network meta-analysis and meta-regression.
Sridharan K, Sivaramakrishnan G. Sridharan K, et al. Int J Clin Pharm. 2024 Apr 25. doi: 10.1007/s11096-024-01736-8. Online ahead of print. Int J Clin Pharm. 2024. PMID: 38664319 Review.
RESULTS: Sixty-six studies (103,347 participants) were included. Fluticasone (OR: 1.46; 95% CI: 1.26, 1.7), mometasone (OR: 2.2; 95% CI: 1.05, 4.6), and beclometasone (OR: 1.7; 95% CI: 1.1, 2.6) were observed with an increased pneumonia risk compared to placebo. Flutica …
RESULTS: Sixty-six studies (103,347 participants) were included. Fluticasone (OR: 1.46; 95% CI: 1.26, 1.7), mometasone (OR: 2.2; 95% …
Umeclidinium plus vilanterol versus fluticasone propionate plus salmeterol for chronic obstructive pulmonary disease: a meta-analysis of randomized, controlled trials.
Zhai C, Wang F, Xu R, Sun X, Ma W, Wang L. Zhai C, et al. Postgrad Med J. 2024 Apr 23:qgae054. doi: 10.1093/postmj/qgae054. Online ahead of print. Postgrad Med J. 2024. PMID: 38652265
This meta-analysis aims to assess the efficacy and safety of UMEC/VI compared with fluticasone propionate plus salmeterol (FP/SAL). METHODS: A systematic search was conducted by a trained medical research librarian across MEDLINE, EMBASE, Cochrane Central Register of Contr …
This meta-analysis aims to assess the efficacy and safety of UMEC/VI compared with fluticasone propionate plus salmeterol (FP/SAL). M …
Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany.
Beeh KM, Rothnie KJ, Claussen J, Hardtstock F, Knapp RK, Wilke T, Czira A, Compton C, Ismaila AS. Beeh KM, et al. Int J Chron Obstruct Pulmon Dis. 2024 Apr 17;19:945-956. doi: 10.2147/COPD.S431291. eCollection 2024. Int J Chron Obstruct Pulmon Dis. 2024. PMID: 38646606 Free PMC article.
PATIENTS AND METHODS: Retrospective cohort study of patients with COPD and 1 prescription for single-inhaler triple therapy (SITT; fluticasone furoate/umeclidinium/vilanterol [FF/UMEC/VI] or beclomethasone dipropionate/glycopyrronium bromide/formoterol [BDP/GLY/FOR]) or mu …
PATIENTS AND METHODS: Retrospective cohort study of patients with COPD and 1 prescription for single-inhaler triple therapy (SITT; flutic …
Cost-effectiveness analysis of fluticasone furoate/umeclidinium bromide/vilanterol and umeclidinium bromide/vilanterol in the management of moderate and severe COPD in China.
Zhou Y, Duan S, Zhang L, Peng F. Zhou Y, et al. Respir Med. 2024 May;226:107632. doi: 10.1016/j.rmed.2024.107632. Epub 2024 Apr 16. Respir Med. 2024. PMID: 38621548
OBJECTIVE: A study has analyzed the long-term cost-effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol combination therapy (FF/UMEC/VI) versus umeclidinium bromide/vilanterol dual therapy (UMEC/VI) in the treatment of moderate or severe chronic obstructive …
OBJECTIVE: A study has analyzed the long-term cost-effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol combination t …
Nanoscale colocalized thermal and chemical mapping of pharmaceutical powder aerosols.
Zhang J, Khanal D, Chan HK, Banaszak Holl MM. Zhang J, et al. Int J Pharm. 2024 May 10;656:124116. doi: 10.1016/j.ijpharm.2024.124116. Epub 2024 Apr 12. Int J Pharm. 2024. PMID: 38615803
Here, we employ nano-thermal analysis (nanoTA) to probe the nanothermal domain of a pharmaceutical aerosol formulation containing a mixture of fluticasone propionate (FP), salmeterol xinafoate (SX), and excipient lactose, which is widely used to treat asthma and chronic ob …
Here, we employ nano-thermal analysis (nanoTA) to probe the nanothermal domain of a pharmaceutical aerosol formulation containing a mixture …
Comparative Efficacy of Budesonide/Formoterol Versus Fluticasone/Salmeterol in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.
Shang N, Liu Y, Jin Y. Shang N, et al. COPD. 2024 Dec;21(1):2328708. doi: 10.1080/15412555.2024.2328708. Epub 2024 Apr 4. COPD. 2024. PMID: 38573085
BACKGROUND/OBJECTIVE: To compare the efficacy of budesonide/formoterol (BF) versus fluticasone/salmeterol (FS) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). ...
BACKGROUND/OBJECTIVE: To compare the efficacy of budesonide/formoterol (BF) versus fluticasone/salmeterol (FS) in patients with moder …
5,260 results